Zymeworks/$ZYME

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Zymeworks

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Ticker

$ZYME
Primary listing

Industry

Biotechnology

Employees

299

Zymeworks Metrics

BasicAdvanced
$998M
-
-$1.50
1.17
-

What the Analysts think about Zymeworks

Analyst ratings (Buy, Hold, Sell) for Zymeworks stock.

Bulls say / Bears say

Zymeworks' lead product, zanidatamab, received approval from China's NMPA for treating HER2-positive biliary tract cancer, expanding its market reach and potential revenue streams. (Zymeworks Press Release)
The company reported a significant increase in Q1 2025 revenue to $27.1 million, up from $10.0 million in Q1 2024, indicating strong financial growth. (Zymeworks Press Release)
Analysts at Lifesci Capital initiated coverage with an 'outperform' rating and a $30.00 price target, suggesting confidence in the company's future performance. (MarketBeat)
HC Wainwright reaffirmed a 'neutral' rating with a $12.00 price target, indicating potential concerns about the company's valuation or growth prospects. (MarketBeat)
Despite recent approvals, Zymeworks remains a clinical-stage company with ongoing expenses and no guarantee of future product success, posing financial risks. (Zymeworks Press Release)
The biotechnology sector is highly competitive, and Zymeworks faces challenges from larger, more established companies with greater resources. (Zymeworks Press Release)
Data summarised monthly by Lightyear AI. Last updated on 13 Jul 2025.

Zymeworks Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Zymeworks Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ZYME

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs